AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 81 min read$MCK

Rutledge Napoleon B JR sold $102K of MCK

Rutledge Napoleon B JR (SVP, Controller & CAO) sold 133 shares of MCKESSON CORP (MCK) at $764.00 ($0.10M total) on 2026-06-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Rutledge Napoleon B JR
Published Jun 8, 2026, 6:54 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 8, 2026, 6:57 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$MCK
Neutral
high confidence
Mentioned
$MCK
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MCKNeutralLow
01

Why it matters

The only new fact is the officer’s sale details (133 shares at $764/share) under a pre-arranged 10b5-1 plan; it does not include any company-specific operational or financial update.

02

Market read

A routine, pre-arranged insider sale is unlikely to materially change near-term trading expectations for MCK.

03

What to watch

Traders may check whether there are multiple recent insider sales or larger off-plan transactions; this filing alone is not enough.

Relevance 3/10Novelty 2/10Timing: Filed 2026-06-08; sale executed 2026-06-05.

Background

The article summarizes an SEC Form 4 insider transaction for McKesson (MCK) filed on EDGAR.

Company-level read

Ticker impact

$MCKNeutralHigh confidence
Context

SEC Form 4 shows Mckesson officer Rutledge sold 133 shares at $764/share under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move from this filing alone.

Evidence & confidence

The disclosure is a small, pre-arranged 10b5-1 sale by an officer; it does not indicate new company fundamentals or guidance.

Market effects

Sector

No sector read-through; this is a single, small insider transaction with no stated corporate event.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even 10b5-1 sales can coincide with private information, but the article provides no evidence beyond the plan designation.

Key entities

  • issuer
    MCK

    McKesson Corp; subject of the Form 4 insider transaction disclosure.

  • insider
    Rutledge Napoleon B JR

    SVP, Controller & CAO who sold shares under a 10b5-1 plan.

Read at source← All news

Related articles

AUG 8
$MCKMed

McKesson Q1 Earnings Call Highlights

McKesson (NYSE: MCK) reported Q1 results supported by higher prescription and specialty volumes, partially offset by lower branded-drug pricing. GLP-1 distribution revenue rose to $15B, up about $3B (24%). Full-year guidance calls for North American Pharmaceutical revenue growth of 4% to 8%. Oncology & Multispecialty profit rose 41% to $405M. McKesson repurchased $2.5B shares and expects FY27 FCF $4.5B to $4.9B.

finance.yahoo.com6 min
AUG 6
$MCKMedAI 8/10

Highlights of McKesson’s (MCK) Q1 2027 earnings report

McKesson (MCK) reported Q1 fiscal 2027 results. Adjusted earnings rose to $9.93 per share from $8.26 a year earlier, beating analysts. Unadjusted net income was $614 million, or $5.17 per share. Revenue increased to $105.4 billion from $97.83 billion. The company raised FY27 adjusted EPS guidance to $44.20 to $45.00.

news.alphastreet.com2 min
AUG 5
$MCKHighAI 9/10

[MCK Q1 2027 Earnings Call] McKesson Lifts Full-Year EPS Target as North American Pharma Profit Soars 19% — BigGo Finance

McKesson reported fiscal Q1 2027 revenue of $105.4B, up 8%, and adjusted EPS of $9.93, up 20%, citing stronger North American Pharmaceutical margins. North American Pharma operating profit rose 19% to $894M on 5% revenue growth, with GLP-1 distribution revenue at $15B (+24%). McKesson raised full-year adjusted EPS guidance to $44.20–$45.00 and returned $2.6B to shareholders.

finance.biggo.com4 min